After a GLP-1: Cleveland Clinic Compares Five Paths in 20,486 Patients
About 11% of US adults were using a GLP-1 medication for weight loss in 2026, up from 3% in 2024, according to the Gallup National Health and Well-Being Index cited in a Cleveland Clinic announcement. Cost, insurance limits and side effects lead many people to stop. The new study, published in eClinicalMedicine and presented at ObesityWeek on November 15, asked a practical question: what happens over the next two years, depending on what a patient does next?
The study
Researchers analyzed health records for 20,486 Cleveland Clinic patients who used semaglutide or tirzepatide for at least three months between 2021 and 2023. They compared five strategies and measured average weight loss at two years:
- Bariatric surgery: about 28% of body weight
- Switching between semaglutide and tirzepatide: about 16%
- Staying on the original medication: nearly 11%
- Moving to another obesity medication: about 8%
- Stopping with no further treatment: about 4%
Details worth knowing
- Among people who started on semaglutide, those who switched to tirzepatide lost more than those who stayed. Among people who started on tirzepatide, staying put was linked to more weight loss than switching to semaglutide.
- The "another medication" group used drugs such as liraglutide, phentermine-topiramate, naltrexone-bupropion and orlistat.
- For people with type 2 diabetes, surgery gave the biggest A1C improvement at one year, followed by switching, staying on the original drug, and moving to another medication.
- People who stopped all treatment saw minimal improvement in blood sugar and blood pressure. Those who continued treatment had larger blood pressure reductions.
How to read it
This is an analysis of health records, not a randomized trial. People who chose each path may differ in ways the data cannot fully capture, so the results do not prove that switching beats staying. They do show a consistent pattern: the worst outcomes came from stopping with nothing to replace the treatment.
That fits an earlier Cleveland Clinic analysis of nearly 8,000 patients, which found that many people who stopped later restarted a medication or tried another treatment. For more on this, see our posts on what happens when you stop a GLP-1 and bariatric surgery after GLP-1 intolerance.
If you are thinking about stopping
- Decide with your provider what comes next before you stop, not after.
- If cost or coverage is the reason, ask about a switch or a lower maintenance dose rather than stopping entirely.
- Keep tracking weight, measurements and blood pressure. Trends over several weeks show early whether a plan is holding.
This article summarizes a published research announcement for general information and is not medical advice. Content was rephrased for compliance. Consult your healthcare provider before stopping or changing any medication.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment protocol.